Transcriptional Regulation of the Intestinal Cancer Stem Cell Phenotype by Gleizes, Antoine et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 12
Transcriptional Regulation of the Intestinal Cancer
Stem Cell Phenotype
Antoine Gleizes, Vincent Cavaillès and
Marion Lapierre
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/intechopen.71859
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited. 
Antoine Gleizes, Vincent Cavaillès and Marion Lapierre
Additional information is available at the end of the chapter
Abstract
Colorectal cancer (CRC) is one of the most frequent cancers worldwide. Current treat-
ments include surgery and chemotherapy, but disease recurrence occurs frequently. The 
continuous renewal of intestinal epithelium relies on the presence of intestinal stem cells 
that are also at the origin of CRC and contribute to therapy resistance and metastatic dis-
semination. Several nuclear signaling pathways and transcription factors regulate both 
intestinal cell homeostasis and tumorigenesis. However, the transcriptional events that 
govern the emergence of aggressive therapy-resistant cancer stem cells are still poorly 
defined. This review summarizes the relevance of transcription factors in intestinal stem 
cell biology and their involvement in colon cancer development and drug resistance.
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1. Introduction
Colorectal cancer (CRC) is one of the most frequent cancers worldwide. The current standard-of-
care management includes surgery, radiotherapy and chemotherapy, sometimes in association 
with targeted agents to block tyrosine kinase receptors or their ligands. However, cancer recurs 
in 30–50% of patients [1].
The intestinal epithelium is continuously renewing, thanks to the presence of multipotent 
stem cells (SCs) within the intestinal crypts that give rise to all the differentiated cell types [2]. 
Different signaling pathways, including Wnt and Notch, and transcription factors are involved 
in intestinal development, homeostasis and maintenance of the intestinal SC properties [3]. 
These signaling cascades must be finely controlled because their deregulation is involved in gut 
© 2018 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
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tumorigenesis. Importantly, recent studies suggest that tumor-initiating cells or cancer stem 
cells (CSCs) can regenerate a tumor and might be at the origin of CRC [4, 5]. Thus, a better 
understanding of CSC function in tumor initiation, progression and resistance to treatment is 
necessary to improve the screening, prevention and clinical management of patients with CRC.
In this review, we propose an overview of key transcriptional regulations that are involved 
in intestinal SC/CSC biology. We present the major signaling pathways and the main tran-
scription factors involved in intestinal homeostasis as well as their roles in the transcriptional 
regulation of intestinal CSCs.
2. The intestinal epithelium and the stem cell compartment
The main functions of the small intestine are food digestion and absorption and production 
of gastrointestinal hormones. It is subdivided in duodenum, jejunum and ileum, and is one 
of the most rapidly self-renewing tissues [6]. It is characterized by the presence of villi and 
Lieberkühn crypts. The large intestine (cecum, colon and rectum) is specialized in compact-
ing stool for rapid excretion, and is arranged in multiple crypts associated with a flat luminal 
surface. It shows slower renewal capacities than the small intestine [7].
The intestinal epithelium develops from the embryonic endoderm [8] and its cellular com-
position is quite similar along the entire intestinal tract. The intestine incredible self-renewal 
capacity is supported by the SC compartment located at the bottom of the crypts. Specifically, 
transit-amplifying (TA) cells undergo four to five rounds of rapid cell division and then move 
out of the crypt and terminally differentiate into enterocytes, goblet cells, Tuft cells and entero-
endocrine cells (Figure 1). These differentiated cells continue to move up along the villus and 
die by anoikis 2 or 3 days after having reached the villus tip. Paneth cells also derive from intes-
tinal SC, but migrate downwards and settle at the crypt base where they live for 6–8 weeks [9]. 
Two other cell types have been detected in the intestinal epithelium: M cells that are associated 
with Peyer’s patches and Cup cells that are located in the ileum.
To date, two SC populations have been identified in the crypts, highlighting the high plas-
ticity of the intestinal epithelial SC compartment. The first one corresponds to crypt-based 
columnar (CBC) cells that express the leucine-rich receptor, LGR5 and are interspersed 
between Paneth cells (Figure 1). CBC cells are required for the long-term maintenance of the 
self-renewing epithelium. Indeed, they cycle steadily to produce the rapidly proliferating TA 
cells that can differentiate into all lineages [6]. In the colon, LGR5+ cells are considered to be 
SCs because they are pluripotent and can maintain epithelial cell self-renewal over long peri-
ods of time. However, LGR5+ cells in the small intestine seem to divide more actively than in 
the colon, possibly due to differences in the epithelial turnover rates [6].
The second crucial SC population corresponds to ‘reserve’ SCs that can be rapidly recruited 
to maintain epithelial homeostasis following injury [7]. They are located at position four from 
the crypt base (hence, the name of +4 SCs) and are generally considered to be relatively qui-
escent and resistant to acute injury (Figure 1). This population was discovered by Potten et al. 
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and was described as the only one responsible for the maintenance of intestinal homeosta-
sis, but without counterpart in the colon [10]. They can retain DNA labels (a surrogate SC 
marker), possibly due to their infrequent replication or selective retention of labeled DNA 
during division. Their relative quiescence also explains their resistance to radiation. This SC 
population was identified thanks to its strong and localized expression of the BMI1 gene that 
encodes a component of the Polycomb repressor complex [7]. Lineage tracing of these cells 
revealed strict terminal differentiation toward the Paneth cell lineage. However, following 
injury, this population can start cycling and show typical intestinal SC activity and multipo-
tency [11]. These features are typical of SCs, despite the fact that, differently from CBC cells, 
they do not generate all epithelial lineages.
3. Colorectal cancer and intestinal cancer stem cells
3.1. Colorectal cancer
Genetic or epigenetic changes can lead to deregulated cell proliferation, resulting in tumor 
growth [12]. In the intestine, tumors start with the formation of small lesions called aberrant 
crypt foci (ACF). ACF expansion gives rise to an adenoma that can progress to in situ carcinoma 
Figure 1. Schematic representation of the intestinal epithelium and the hierarchy of intestinal lineages. Self-renewal of 
the intestinal epithelium is fueled by small intestinal stem cells (at the bottom of the crypt) that give rise to progenitor 
cells. These can subsequently differentiate into the mature cell types required for normal gut function.
Transcriptional Regulation of the Intestinal Cancer Stem Cell Phenotype
http://dx.doi.org/10.5772/intechopen.71859
275
and finally to invasive adenocarcinoma [12]. Studies in humans and in animal models suggest 
that intestinal tumor development is a process where each successive genetic change confers 
growth advantage to tumor cells. Collectively, these genetic changes in cancer cells allow tumor 
progression through different stages [12]. Indeed, CRC development is considered as a para-
digm of stepwise tumorigenesis with subsequent histopathological stages that precede invasive 
neoplastic growth and are associated with a progressively increasing number of specific genetic 
aberrations [11].
3.2. Intestinal cancer stem cells
Intriguingly, the biology of intestinal SCs and CRCs is highly interconnected. In many intestinal 
malignancies, it is assumed that the ‘cell of origin’ is a SC that acquired the initial mutation(s) 
necessary for malignant conversion [11]. These genetic alterations promote self-sufficiency in 
growth signals, insensitivity to growth-inhibitory signals, programmed cell death evasion, 
limitless replicative potential, sustained angiogenesis, tissue invasion and ultimately metas-
tasis formation [13]. Additionally, heterogeneously differentiated cell types are found in indi-
vidual CRC specimens, contributing to the idea that such tumors are ‘caricatures’ of the normal 
intestinal tissue. This notion is further strengthened by the discovery of SC-like cancer cells 
that express intestinal SC markers and display multipotency and self-renewal capacities.
It is thought that intestinal CSCs are the cells that drive tumor growth and progression [11]. 
Indeed, intestinal CSCs, but not intestinal SCs, can regenerate tumors upon transplantation in 
animals [14]. CSCs are defined by four main characteristics: (i) they can be serially transplanted 
for multiple generations because of their self-renewal capacity; (ii) CSCs can generate bulk 
populations of non-tumorigenic cells by asymmetrical division, which is consistent with the 
hierarchical model of tumor development. Conversely, symmetrical division allows CSC main-
tenance within the tumor; (iii) CSCs retain their tumorigenic potential when transplanted into 
animals and (iv) CSCs can be separated from non-SCs using specific surface markers [14, 15]. In 
the last decades, the concept of CSC hierarchical arrangement has changed our understanding 
of tumor cell heterogeneity. The current CSC model postulates that CSCs reside at the top of 
the tumor hierarchy and differentiate unidirectionally into highly proliferative non-CSCs [12].
4. Nuclear signaling pathways that control intestinal CSCs
In this part, we will focus on the major signaling pathways and transcription factors that are 
involved in the transcriptional regulation of intestinal SC/CSCs (Figure 2) and that could con-
sequently be associated with tumor development/progression and/or cancer cell resistance 
to therapy.
4.1. The Wnt pathway and its effectors
4.1.1. The Wnt pathway
The Wnt pathway is involved in many biological processes and is essential for epithelial 
intestinal homeostasis (Figure 2) [16]. Accumulation and translocation of β-catenin into the 
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nucleus are the hallmark of the canonical Wnt pathway activity. In the absence of Wnt ligands, 
β-catenin is phosphorylated, ubiquitinylated and degraded by the proteasomal machinery. 
Binding of Wnt ligands to their receptors results in the cytoplasmic accumulation of β-catenin 
that then translocates into the nucleus where it functions as a transcriptional co-activator of 
Wnt-target genes. The best characterized binding partners of β-catenin in the nucleus are the 
members of the lymphoid enhancer factor (LEF)/T cell factor (TCF) DNA-binding transcrip-
tion factors [17]. Some of the downstream targets of the Wnt signaling pathway, such as SOX9 
and KLF4/5, are involved in the control of the intestinal CSC phenotype and in CRC develop-
ment and will be described below (see Sections 4.1.2 and 4.1.3).
In up to 80% of colorectal carcinomas, mutations in molecules that are part of the Wnt/β-catenin 
pathway (notably truncating mutations in the Apc gene) lead to the formation of constitutive 
nuclear TCF/β-catenin complexes and to uncontrolled transcription of TCF-4 target genes [18]. In 
Figure 2. Schematic representation of the major signaling pathways involved in cancer stem cell biology. A gradient of 
BMP and Hh signaling, with relatively high activity in the villus and less activity within the crypt, regulates cell renewal 
and lineage specification. Wnt and Notch signaling gradients in the opposite direction (highest expression at the crypt 
base) play an important role in maintaining the stem cell compartment.
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the mouse, specific deletion of the Apc gene in LGR5+ SCs triggers the formation of many LGR5+ 
adenomas in the small and large intestine [5]. Similarly, lack of β-catenin repression in intestinal 
+4 SCs promotes the formation of BMI1+ adenomas [19]. Moreover, loss of APC negative control 
induces constitutive nuclear β-catenin/TCF complex activation and hyper-proliferation of the SC 
compartment [19].
The Wnt signaling pathway has a role also in human intestinal CSCs. In spheroid cultures of 
CSCs isolated from biopsies of patients with CRC, Wnt expression is heterogeneous. Injection of 
Wnthigh cells in mice results in more effective tumor formation compared with Wntlow cells. The 
heterogeneous Wnt expression pattern is maintained in the tumors and is related to the expres-
sion of several intestinal SC markers, such as LGR5 and ASCL2 [20]. Additionally, colonospheres 
developed from human CSCs show increased β-catenin expression, associated with transcrip-
tional activation of TCF/LEF [21]. Hence, activation of Wnt/β-catenin signaling can convert intes-
tinal SCs into CSCs, which corresponds to the first step of malignant transformation [19].
Several studies tried to correlate β-catenin activation/expression level with the outcome of patients 
with CRC. For instance, in 2007, Lugli et al. analyzed tissue microarray data on more than 1400 
CRC biopsies and found that high level of β-catenin nuclear expression is an independent adverse 
prognostic factor [22].
4.1.2. SOX9
The SRY-related high-mobility group box 9 (SOX9) gene is a physiological target of the TCF/β-
catenin complex that promotes cell proliferation. This key terminal effector of the Wnt pathway 
is required for +4 SC differentiation into Paneth cells [23]. In the intestinal epithelium, SOX9 
expression pattern in the SC compartment almost perfectly overlaps with that of the prolif-
erative marker Ki-67. Interestingly, SOX9 positively regulates its own expression in many cell 
types and exerts a negative feedback-loop on TCF/β-catenin activity, leading to restriction of 
intestinal SC proliferation [23, 24].
SOX9-deficient mice exhibit higher cell proliferation, extensive colon hyperplasia with numerous 
enlarged crypts. However, SOX9 deletion is not sufficient to induce malignancy [25]. Moreover, 
SOX9 overexpression in human CRC cells results in cell cycle progression and apoptosis bypass, 
due to increased BMI1 gene expression [26]. Additionally, in colon epithelial cells, high SOX9 
expression is associated with undifferentiated states, SC-like properties and high LGR5 mRNA 
level in vitro [27]. SOX9 has several pro-oncogenic properties, including the ability to promote 
cell proliferation, to inhibit senescence and to collaborate with other oncogenes in neoplastic 
transformation [26]. However, recent in vitro and in vivo studies have described SOX9 tumor 
suppressor activities in CRC cells. Specifically, SOX9 inhibits β-catenin activity by interacting 
physically with this protein and removing it from chromatin. It also decreases expression of the 
c-Myc oncogene, a target of the Wnt/β-catenin pathway [28].
The strong expression of SOX9 in CRC cells due to the constitutive activity of the Wnt pathway 
can contribute to cancer progression and/or influence tumor differentiation. SOX9 displays mis-
sense or frameshift mutations in almost 10% of CRC [29]. SOX9 mutation rate is higher in more 
advanced tumors and is correlated with activated KRAS, an oncogene frequently mutated during 
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CRC development, thus facilitating transformation and tumor progression [29]. Furthermore, a 
SOX9 splice variant (MiniSOX9) that contains the HMG domain responsible for binding to DNA 
but devoid of the trans-activating domain has been discovered [30]. MiniSOX9 inhibits SOX9 
activity by a dominant-negative effect in vitro and can promote the Wnt/β-catenin pathway, 
resulting in β-catenin over-activation. In addition, strong MiniSOX9 expression is observed in 
CRC tumor tissue, while it is undetectable in the adjacent normal tissue [30]. Wild type and many 
SOX9 mutants regulate tumor proliferation capacity, notably through regulation of the CSC pool. 
Nevertheless, SOX9 protein level could not be clearly associated with patient prognosis [31].
4.1.3. Krüppel-like factors (KLF)
4.1.3.1. KLF4
KLF4 was originally identified as a gut-enriched transcription factor in the intestine and is 
expressed in terminally differentiated columnar intestinal epithelial cells [32]. KLF4 regulates 
intestinal epithelial homeostasis and has a critical role in the development and terminal dif-
ferentiation of goblet cells [32]. In human HT-29 CRC cells, KLF4 inhibits cell proliferation by 
blocking progression from the G1 to S phase of the cell cycle through inhibition of cyclin D1 
expression [33].
Moreover, mutations in the Wnt/β-catenin pathway are associated with KLF4 downregulation 
in human CRC cell lines. Indeed, KLF4 is an indirect APC target and is considered to be a repres-
sor of BMI1 transcriptional activity [34, 35]. Furthermore, using a KLF4 inducible system in CRC 
cell lines, it was demonstrated that KLF4 reduces colony formation, cell migration and inva-
sion [34]. Additionally, KLF4 overexpression in human adenocarcinoma cells leads to reduced 
[3H]-thymidine uptake, whereas inhibition of KFL4 expression increases DNA synthesis, con-
firming that KLF4 plays an essential role in colon cell growth arrest [36]. Surprisingly, despite its 
tumor suppressor activity, KLF4 is overexpressed in colon CSC-enriched spheroids compared 
with the parental CRC cells from which the spheroids were derived [37]. Moreover, KLF4 knock-
down affects the stemness phenotype and decreases the malignant profile of these CSC-enriched 
spheroid cells, in line with its role in reprogramming murine fibroblasts into stem cells [37, 38].
In agreement with its tumor suppressor activity, KLF4 expression is frequently lost in CRC and its 
downregulation is strongly associated with tumor development. Moreover, loss of heterozygos-
ity on chromosome 9q31, where the KLF4 gene is localized, is frequently found in human CRC, 
and could lead to uncontrolled cell proliferation and to a SC-like phenotype of differentiated cells 
[33]. Low KLF4 expression levels are also found in colon adenomas and metastases [33]. Lee et al. 
confirmed that KLF4 mRNA expression levels are lower in CRC tumor tissue compared with nor-
mal tissue [39]. However and surprisingly, they observed that high KLF4 level in normal tissue is 
correlated with high KLF4 expression in tumors and is associated with poor patient survival [39].
The conflicting results between clinical studies concerning KLF4 prognostic value could be 
explained by the differential regulation of KLF4 mRNA and protein expression in CRC or by 
the presence also of KLF4+ stromal cells in the tumor samples. Additional investigations are 
needed to elucidate these data; nevertheless, KLF4 expression levels in normal and tumor tis-
sues are prognostic markers for CRC.
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4.1.3.2. KLF5
The transcription factor KLF5 can interact with several components of different signaling 
pathways (e.g., the Wnt, Hippo, TGF-β and Notch signaling cascades) and mediate their 
activity [40]. In physiological conditions, KLF5 is strongly expressed by intestinal progenitor 
and stem cells, suggesting a role in cell proliferation control [41].
Stable KLF5 overexpression in HT-29 CRC cells promotes spheroid formation [40]. Conversely, 
deletion of the KLF5 gene in mouse LGR5+ SCs promotes β-catenin nuclear localization and 
the appearance of abnormal apoptotic cells in the intestinal crypts, due to inhibition of their 
proliferation and survival capacities [41]. In agreement, KLF5 is required for the tumor-ini-
tiating activity of β-catenin during intestinal tumorigenesis in ApcMin mice [41]. Inhibition of 
KLF5 gene expression in CRC cell lines reduces cell proliferation and transformation as well as 
anchorage-independent growth [42].
In patients with CRC, intestinal tumor progression is associated with KLF5 gene upregulation in 
the primary tumor and also in metastases, compared with healthy tissues [41]. Moreover, com-
parative genomic hybridization (CGH) array analysis of human CRC samples highlighted the 
frequent chromosomal amplification of the KLF5 locus [41]. CRC samples with mutated KRAS 
also display KLF5 upregulation, associated with increased cell proliferation [42]. As activating 
KRAS mutations are found in more than 50% of CRC, KLF5 appears to be an important down-
stream mediator of activated KRAS during CRC development. These findings indicate that 
KLF5 is a major regulator of intestinal SC proliferation in normal and pathological conditions.
4.2. The Notch pathway and BMI1
4.2.1. The Notch pathway
The Notch signaling cascade is one of the major pathway involved in intestinal homeostasis 
and in the direct regulation of cell fate [43]. The initiating step of the Notch signaling cas-
cade is the interaction between one of its five ligands (Delta-like1/3/4, Jagged1/2) and a Notch 
receptor (Notch1–4). Upon ligand binding, the receptor conformational change through pro-
teolytic cleavage leads to nuclear translocation of cleaved Notch intracellular domain (NICD) 
and its association with the DNA-binding transcription factor CSL (also called RBP-Jκ). This 
turns the CSL complex from a transcriptional repressor into a transcriptional activator. The 
best known targets of the CSL/NICD complex are members of the HES gene family and their 
homologs, the Hey (also called HERP) gene family of basic helix-loop-helix transcription fac-
tors. This is known as the canonical Notch pathway [17, 43, 44].
In the colon, Notch signaling is an essential gatekeeper of intestinal progenitors and clearly 
plays an important role in the maintenance of the colon crypt compartment [45] (Figure 2). 
Using small-molecule inhibitors and short hairpin RNA-mediated knock-down, it has been 
demonstrated that Notch prevents apoptosis of colon cancer-initiating cells (CCICs) and is crit-
ical for self-renewal [46]. Moreover, the Notch pathway supports slow-cycling BMI1+ CCICs, 
by promoting their self-renewal, tumorigenicity and chemoresistance in tumor xenografts [47].
Gene Expression and Regulation in Mammalian Cells - Transcription Toward the Establishment of Novel Therapeutics280
In CRC, the Notch pathway is strongly activated compared with normal tissue. Moreover, 
expression analysis of resection biopsies from patients with CRC showed that Notch1 expres-
sion level is correlated with poor prognosis and is a good predictive marker of cancer pro-
gression [48]. Intriguingly, the expression level of Notch2 is negatively correlated with that of 
Notch1 in CRC and Notch2 has anti-tumoral properties [48]. These opposite features could be 
used to develop a fine prognostic marker of CRC progression and recurrence.
4.2.2. BMI1
BMI1 is a downstream target of Notch signaling and a key component of the Polycomb group 
[49]. BMI1 is expressed in almost all tissue types and regulates a myriad of cellular processes 
that are critical for cell growth, cell fate decision, development, senescence, aging, DNA dam-
age repair, apoptosis and SC self-renewal [49, 50]. BMI1 is highly expressed in intestinal SCs 
and isolated BMI1+ cells can generate epithelial organoids in culture [7]. Additionally, BMI1 
loss decreases murine intestinal SC proliferation and promotes their differentiation into goblet 
cells [49]. BMI1 also contributes to the tumor-initiating and self-renewal abilities of human 
CRC cells because its downregulation inhibits tumor cell growth and is associated with reduc-
tion of tumor-initiating cells [51]. Moreover, BMI1 is involved in intestinal CSC invasion and 
migration. Indeed, a recent study demonstrated that BMI1 represses E-cadherin expression in 
colon CSCs, thus promoting metastasis formation via epithelial to mesenchymal transition [50].
Altogether, these data strongly support BMI1 role in the maintenance of the intestinal CSC pheno-
type. In agreement, clinical studies showed that BMI1 expression is a negative prognostic marker 
in CRC [52]. BMI1 mRNA and protein are overexpressed in colorectal adenomas and carcinomas 
compared with normal tissues [53]. A gradient of BMI1 expression has been reported in human 
colon precancerous and cancerous tissues and is correlated with the cancer stage, suggesting that 
BMI1 contributes to CRC progression [53].
Indeed, BMI1 is considered to be a negative CRC prognostic biomarker, and patients with 
BMI1-positive tumors are at higher risk of disease recurrence and/or metastases compared with 
those with BMI1-negative tumors. As BMI1 has a role in maintaining the intestinal CSC pheno-
type, high BMI1 expression could indicate the presence of a large CSC population in the tumor. 
Consequently, high proportion of CSCs in a tumor could be an indicator of poor prognosis [31, 
54, 55].
4.3. Other signaling pathways
4.3.1. The Hedgehog pathway
The Hedgehog (Hh) signaling pathway is a key regulator of intestinal homeostasis. Hh proteins 
are part of a family of secreted proteins that are involved in the development and maintenance 
of the gastrointestinal tract [17]. Aberrant activation of the Hh signaling pathway is associated 
with tumorigenesis in various tissues. The roles of Hh signaling differ at each CRC stage, from 
adenoma to adenocarcinoma [56]. Moreover, Sonic Hedgehog (SHH), one of the Hh effectors, 
promotes CRC development, while Indian Hedgehog (IHH) inhibits CRC formation [56].
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IHH regulates intestinal SC fates by interfering with the maturation and localization of the 
underlying stromal cells that in turn generate signaling molecules needed for the maintenance 
of the intestinal SC niche [56] (Figure 2). IHH, expressed by differentiated enterocytes, indi-
rectly inhibits Wnt signaling at the crypt base and reduces the number of proliferating precur-
sor cells [17, 57]. A decrease in Hh signaling is correlated with the expansion of the intestinal 
SC pool, with blunted enterocyte differentiation and activation of the Wnt pathway. Moreover, 
IHH gene knock-out leads to intestinal SC accumulation [57]. In addition, specific Hh activa-
tion in murine stromal cells induces complex transcriptional changes, leading to loss of colon 
SC-specific gene expression and upregulation of epithelial differentiation markers [58]. Most 
of the components of the Hh signaling pathway are upregulated (mRNA and protein) in CRC, 
with the exception of IHH that appears to be downregulated. Overexpression of members of 
the Hh signaling pathway is associated with poor survival and adverse clinical features [59]. 
However, in metastatic CRC, treatment with vismodegib, an Hh pathway inhibitor, in com-
bination with standard chemotherapy, does not significantly improve patient survival [60].
4.3.2. The BMP pathway
The BMP pathway regulates many cellular mechanisms, including apoptosis and cell growth, 
depending on the specific cellular context. BMP ligands are secreted in their active form and 
homodimerize before binding to their cognate BMP receptors (BMPR). SMAD transcription 
factors are the main downstream effectors of BMP signaling that plays key roles in adult gut 
homeostasis, inflammation and cancer.
Specific inhibition of BMP signaling in intestinal epithelial cell does not lead to initiation of 
colon tumors in vivo, while suppression in mesenchymal myofibroblasts is associated with 
spontaneous tumor formation. This suggests that inhibition of BMP signaling in the mesenchy-
mal cells surrounding the intestinal epithelium acts as a trigger of gastrointestinal tumorigen-
esis [61]. Moreover, BMP4 expression is lost in intestinal CSCs, leading to deregulation of the 
proliferative compartment [62].
Nevertheless, it is still unclear whether BMP limits expansion of intestinal epithelial cells by 
repressing LGR5+ intestinal SC self-renewal or by inhibiting epithelial cell proliferation. In addi-
tion, BMP type Ia receptor (Bmpr1a) conditional knock-out in the intestinal epithelium leads to 
intestine hyperplasia with multiple intestinal polyps due to hyperactive SCs [63]. Moreover, in 
these mice, the LGR5+ SC pool is enlarged due to increased survival, allowing better intestinal 
regeneration [63]. Among the BMP family members, BMP2 and BMP4 are specifically involved 
in intestinal CSC regulation by promoting their differentiation and antagonizing Wnt/β-catenin 
signaling [64]. Furthermore, a recent study showed that the transcription factor GATA6 is a key 
regulator of CSC expansion and self-renewal through downregulation of BMP genes [65].
Finally, mutations that affect BMP signaling are frequently observed in patients with juvenile 
polyposis syndrome that is characterized by non-cancerous polyps, as well as in patients with 
progressing CRC. Analysis of SMAD4 expression levels in patients with CRC showed that it 
is downregulated in CRC and associated with poor prognosis [66].
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4.3.3. The Hippo pathway
The Hippo pathway regulates various cellular processes, including cell survival, proliferation 
and differentiation, but has been involved only recently in SC biology [67]. Yes-associated pro-
tein (YAP) and transcriptional co-activator with PDZ binding motif (TAZ) are the central effec-
tor molecules of this signaling cascade and are abundantly expressed in the cytoplasm of both 
proliferating and post-mitotic cells [17, 68].
In cancer, the Hippo pathway inhibits cell proliferation, promotes apoptosis and regulates stem/
progenitor cell expansion. In cancer cells, YAP and TAZ are localized mainly in the nucleus and 
promotes cell and tumor growth. There is considerable evidence that abnormal Hippo signal-
ing is associated with tumor progression and YAP/TAZ overexpression is frequently observed 
in CRC [67]. This overexpression could be linked to Wnt/β-catenin over-activation because YAP 
is a specific target of this pathway. Furthermore, the major components of the Hippo pathway 
(i.e., MST1/2 and MOBKL1A/B) that control YAP/TAZ activity display low expression levels in 
colon carcinomas [69]. YAP deletion in Apcmin mice prevents polyp formation and blocks the dif-
ferentiation of Apc−/− organoids. Moreover, using a mosaic model of Yap and Apc gene deletion 
in intestinal SCs, YAP appears to be dispensable for tumor initiation, but crucial for progression 
of tumor-initiating cells to adenoma [70].
Hippo pathway dysregulation, leading to loss of YAP repression, has been observed in differ-
ent cancer types [71]. In patients with CRC, YAP over-activation is closely related to β-catenin 
over-activation. Moreover, the tyrosine kinase c-Yes is hyper-phosphorylated in 5-fluorouracil-
resistant cells with CSC features, thus preventing YAP nuclear translocation [72]. Finally, YES1 
and YAP levels are correlated with worse prognosis in chemotherapy-treated patients with 
CRC, suggesting that chemotherapy favors the selection of intestinal CSCs with deregulated 
c-Yes and YAP [72].
4.4. Other intestinal CSC-related transcription factors
4.4.1. PXR
Pregnane X Receptor (PXR, NR1I2), a member of the nuclear receptor superfamily, is highly 
expressed in the colon. PXR targets are genes that encode phase I and II metabolic enzymes 
and phase III drug transporters. Members of the nuclear receptor superfamily function as 
ligand-activated transcription factors and play critical roles in nearly every aspect of devel-
opment and adult physiology [73]. Interestingly, it has been reported that the Wnt/β-catenin 
signaling pathway is crucial for PXR activity and notably that β-catenin is required for PXR-
mediated induction of target gene expression [74].
Planque et al. have recently demonstrated that PXR is a potent intestinal CSC phenotype driver 
by regulating a network of downstream genes involved in self-renewal and chemoresistance 
[75]. PXR expression is associated with CSC enrichment, after cell sorting of cancer cells using 
ALDH activity to identify CSCs and after spheroid passaging. In addition, expression of CSC 
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markers and self-renewal are increased in CRC cells with enhanced PXR transcriptional activity 
[75]. PXR expression in intestinal CSCs is also associated with tumor aggressiveness and che-
moresistance [76]. Specifically, PXR increases the oxaliplatin efflux capacity of cancer cells, thus 
reducing the cell drug concentration and preventing its effects on cell proliferation and apopto-
sis [76]. Another study demonstrated that PXR is a master regulator of chemoresistance by regu-
lating genes involved in drug resistance, such as cytochrome P450, multidrug resistance 1 and 
multidrug resistance-associated protein 2 [77]. Furthermore, PXR is associated with poor sur-
vival, particularly after drug treatment. Indeed, in patients with CRC, it allows clonal selection 
after treatment, leading to the emergence of resistant and more aggressive clones with molecular 
signatures of poor prognosis [75, 77].
4.4.2. HOPX
The homeodomain-only protein homeobox (HOPX) is strongly expressed in normal colorectal 
mucosa, and is considered a marker of the +4 SC population in the intestine [78]. Conversely, 
HOPX-β (an isoform of HOPX) represses conversion to the CBC phenotype in +4 SCs in 
physiological contexts in mice [78].
HOPX shows tumor suppressor functions in CRC by regulating cell proliferation and 
inhibiting angiogenesis [79]. Microarray data analysis revealed that, in CRC samples, 
HOPX downregulates oncoproteins, such as c-FOS and EGR-1. Moreover, EphA2 (which 
increases tumor invasion and survival) is overexpressed in patients with HOPX gene 
hypermethylation. In addition, HOPX-β promoter is frequently hypermethylated in CRC 
cell lines and tissues. This methylation results in the downregulation of HOPX mRNA and 
protein levels. Importantly, in patients with stage III CRC, HOPX-β promoter hypermeth-
ylation is associated with worse prognosis [79]. Moreover, in patients with CRC, HOPX 
gene hypermethylation is accompanied by increased expression of Cyr61/CCN1, a critical 
downstream member of the Hh signaling pathway that affects the pro-angiogenic tumor 
microenvironment [80].
4.4.3. Sp1
Specificity protein 1 (Sp1) is a transcription factor ubiquitously expressed in mammalian cells 
that recruits the basal transcription machinery. Sp1 is active in all cell types, but it is also 
tightly regulated because Sp1 activity can alter the expression of genes involved in cell cycle 
and growth (including many tumor suppressor genes and oncogenes) in response to signal-
ing pathways and specific cellular conditions [81].
Interestingly, Sp1 levels are higher in colon CSCs than in the parental tumor cells [82]. 
Moreover, siRNA-mediated SP1 silencing suppresses the specific features of CSCs derived 
from CRC cells and promotes apoptosis of colon CSCs in vitro [82]. SP1 silencing also decreases 
the expression of several CSC markers. Hence, colon CSC self-renewal ability, drug resistance 
and metastasis potential could be partially related to high Sp1 expression. In agreement, Sp1 
overexpression correlates with tumor stage and poor prognosis [81].
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5. Conclusion
Cancer management is one of the major issues in our society and therefore, much research is 
focused on improving our understanding of cancer development and progression. Here, we pre-
sented an overview of the transcriptional dysregulation that affect intestinal epithelium homeo-
stasis and that can lead to tumor initiation and development. In the last decade, considerable 
progress has been made in understanding the molecular and cellular mechanisms linked to CRC 
development/progression and a major breakthrough was the identification of cells with CSC 
properties. Studies in mouse models have shown that CRC development is mainly supported by 
intestinal CSCs that can self-renew and generate tumor cell heterogeneity even after in vitro or in 
vivo passaging. However, CSCs do not cycle as fast as cancer cells. This means that the current 
therapies that target cycling cancer cells are not efficient against the relatively quiescent CSCs.
CSC fate and properties are regulated through a wide transcriptional network controlled by 
signaling cascades that often crosstalk and regulate each other (Figure 3).
Figure 3. Transcriptional landscape associated with the CSC phenotype in CRC. Schematic representation of the positive 
(arrows) and negative (bar-ended arrows) regulations between transcription factors and signaling pathways and 
associated with the CSC phenotype within the tumor. ISEM = intestinal subepithelial myofibroblasts.
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Transcription 
factors
Physiological roles Status in CRC CRC-associated 
phenotype
Prognosis References
SOX9 Differentiation of 
Paneth cells
Promotion of SC 
proliferation
Overexpression Cell cycle progression
Apoptosis bypassing 
undifferentiated  
state
No correlation [23–27, 31]
KLF4 Differentiation of 
Goblet cells
Low expression Increased DNA 
synthesis
Uncontrolled cell 
proliferation
CSC-like phenotype
Poor [32, 33, 36, 
39]
KLF5 Promotion of cell 
proliferation
Overexpression Promotion of cell 
proliferation
Increase of cell  
survival capacities
No correlation [41]
BMI1 Promotion of SC 
proliferation and 
renewal
Prevention of 
senescence
DNA damage  
repair
Overexpression Tumor initiation
Self-renewal of CRC 
cells
Promotion of cell 
invasion and  
migration
Poor [31, 49–51, 
53–55]
IHH Differentiation of 
enterocyte cells
Inhibition of cell 
proliferation
Low expression Expansion of the  
CSC pool
Promotion of cell 
proliferation
[17, 56, 57]
SHH Promotion of cell 
proliferation
Overexpression Promotion of CRC 
development
Poor [56, 59]
SMAD Differentiation of 
enterocyte cells
Inhibition of Lgr5+ 
SC expansion
Low expression Poor [61, 66]
YAP/TAZ Promotion of cell 
proliferation
Overexpression 
and 
over-activation
Tumor progression Poor [67, 70, 72]
PXR Increase of 
cholesterol uptake
Promotion of 
intestinal epithelial 
wound healing and 
repair
CSC self-renewal
Drug resistance
Poor [73, 75, 77]
HOPX Maintenance of +4 
SC identity
Low expression Promotion of cell 
proliferation
Promotion of 
angiogenesis
Poor [78, 79]
SP1 Cell cycle and 
growth control
Overexpression CSC renewal ability
Drug resistance
Metastasis potential
Poor [81, 82]
Table 1. Phenotypic outcomes associated with the different transcription factors in normal and tumoral intestinal 
epithelium.
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In this review, we focused on some of these transcription factors and major signaling pathways 
involved in the regulation of the intestinal CSC phenotype and in CRC development. The basis 
of CRC development is the over-activation of the Wnt/β-catenin signaling cascade. Then, the dis-
ruption of other signaling pathways potentiates the oncogenic process by maintaining or even 
amplifying these alterations. Similarly, mutations or altered expression of different transcription 
factors also contribute to the oncogenic network. All these mechanisms concur to promote tumor 
growth and aggressiveness due to CSC enrichment. Moreover, some of these pathways and 
transcription factors might confer chemoresistance to the CSC population and are involved in 
CRC relapse (Table 1). Therefore, they are considered poor prognostic markers. Consequently, 
effective CRC therapies should target not only the highly proliferative cancer cells but also colon 
CSCs, or sensitize them to therapies. These different signaling pathways and their downstream 
effectors could represent biomarkers of CRC progression and therapeutic targets.
To conclude, these data do not give the solution on how to cure CRC, but help understand-
ing why its management is not simple. Several topics presented in this review are field of 
active research. Indeed, there are multiple and complex interactions between key signaling 
pathways known to control SC behavior. The knowledge on the transcriptional networks that 
control intestinal CSCs is not complete yet, and some findings are controversial. A better char-
acterization and comprehension of these regulatory mechanisms, notably through network 
analysis, are needed to identify new therapeutic targets in order to improve patient care.
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